A Multisite Retrospective Review of Direct Oral Anticoagulants Compared to Warfarin in Adult Fontan Patients
Tóm tắt
Direct oral anticoagulants (DOACs) are not recommended in adult Fontan patients (Level of Evidence C). We hypothesized that DOACs are comparable to warfarin and do not increase thrombotic and embolic complications (TEs) or clinically significant bleeds. We reviewed the medical records of adult Fontan patients on DOACs or warfarin at three major medical centers. We identified 130 patients: 48 on DOACs and 107 on warfarin. In total, they were treated for 810 months on DOACs and 5637 months on warfarin. The incidence of TEs in patients on DOACs compared to those on warfarin was not increased in a statistically significant way (hazard ratio [HR] 1.7 and p value 0.431). Similarly, the incidence of nonmajor and major bleeds in patients on DOACs compared to those on warfarin was also not increased in a statistically significant way (HR for nonmajor bleeds in DOAC patients was 2.8 with a p value of 0.167 and the HR for major bleeds was 2.0 with a p value 0.267). In multivariate analysis, congestive heart failure (CHF) was a risk factor for TEs across both groups (odds ratio [OR] = 4.8, 95% confidence interval [CI] = 1.3–17.6) and bleed history was a risk factor for clinically significant bleeds (OR = 6.8, 95% CI = 2.7–17.2). In this small, retrospective multicenter study, the use of DOACs did not increase the risk of TEs or clinically significant bleeds compared to warfarin in a statistically significant way.
Từ khóa
Tài liệu tham khảo
Jacobs ML, Pourmoghadam KK. Thromboembolism and the role of anticoagulation in the Fontan patient. Pediatr Cardiol. 2007;28:457–64.
Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. Heart Rhythm. 2014;11:e102–65.
Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(12):e81–192.
Firdouse M, Agarwal A, Chan AK, Mondal T. Thrombosis and thromboembolic complications in Fontan patients: a literature review. Clin Appl Thromb Hemost. 2014;20:484–92.
Marrone C, Galasso G, Piccolo R, et al. Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis. Pediatr Cardiol. 2011;32:32–9.
McCrindle BW, Manlhiot C, Cochrane A, et al. Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol. 2013;61:346–53.
Potter BJ, Leong-Sit P, Fernandes SM, et al. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. Int J Cardiol. 2013;168:3940–3.
Seipelt RG, Franke A, Vazquez-Jimenez JF, et al. Thromboembolic complications after Fontan procedures: comparison of different therapeutic approaches. Ann Thorac Surg. 2002;74:556–62.
January CT, Wann LS, Alpert JS, American College of Cardiology/American Heart Association Task Force on Practice Guidelines, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-76.
Kirchhof P, Benussi S, Kotecha D, ESC Scientific Document Group, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.
Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
Giugliano RP, Ruff CT, Braunwald E, ENGAGE AF-TIMI 48 Investigators, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
Granger CB, Alexander JH, McMurray JJ, ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
Patel MR, Mahaffey KW, Garg J, Pan G, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–52.
Yang H, Bouma BJ, Mulder BJM. Non vitamin K antagonist Oral anticoagulants for ThromboEmbolic prevention in adult congenital heart disease (NOTE) investigators. Is initiating DOACs for atrial arrhythmias safe in adults with congenital heart disease? Cardiovasc Drugs Ther. 2017;31:413–7.
Sarubbi B, Scognamiglio G, Merola A, et al. New oral anticoagulants in complex adult congenital heart disease patients: a single centre experience. J Atr Fibrilation (Venice Arrhythmias 2015).
Cheng K, Harrogate S, Orchard E. The use of novel oral anticoagulants in adult congenital heart disease: a single center experience. Am J Cardiol. 2016;117:312–3.
Egbe AC, Connolly HM, McLeod CJ, et al. Thrombotic and embolic complications associated with atrial arrhythmia after Fontan operation: role of prophylactic therapy. J Am Coll Cardiol. 2016;68:1312–9.
Pinto C, Samuel BP, Ratnasamy C, Vettukattil JJ. Thrombosis in Fontan patient on apixaban. Int J Cardiol. 2015;182:66–7.
Pujol C, Niesert AC, Engelhardt A, et al. Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J Cardiol. 2016;117:450–5.
Khairy P, Van Hare GF. Reply to the Editor-Concern regarding adult congenital heart disease arrhythmia guidelines. Heart Rhythm. 2015;12:e33–4.
Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, Lipczynska M, Podolec P, Undas A. Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. J Thorac Cardiovasc Surg. 2014;147:1284–90.
Georgekutty J, Kazerouninia A, Wang Y, et al. Novel oral anticoagulant use in adult Fontan patients: a single center experience. Congenit Heart Dis. 2018;13(4):541–7.
Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331–9.
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.
Yang H, Veldtman GR, Bouma BJ, et al. Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe. Open Heart. 2019;6(1):e000985.
Yang H, Bouma BJ, Dimopoulos K, et al. Non-vitamin K antagonist oral anticoagulants (DOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. Int J Cardiol. 2020;15(299):123–30.
Pujol C, Müssigmann M, Schiele S, et al. Direct oral anticoagulants in adults with congenital heart disease - a single centre study. Int J Cardiol. 2020;1(300):127–31.
Stalikas N, Doundoulakis I, Karagiannidis E, et al. Non-vitamin K oral anticoagulants in adults with congenital heart disease: a systematic review. J Clin Med. 2020;9(6):1794.
O’Brien EC, Holmes DN, Thomas LE, et al. Prognostic significance of nuisance bleeding in anticoagulated patients with atrial fibrillation. Circulation. 2018;138(9):889–97.